Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$2.60
0.072.77%
Last update: Oct 19, 4:11 PM
$2.58
0.051.98%
SAB Biotherapeutics Inc (SABS) Stock Price, Quote, News & History
SABSNASDAQ
| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate,...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of SAB Biotherapeutics (NASDAQ:SABS) through any online brokerage.
Other companies in SAB Biotherapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
SAB Biotherapeutics has a consensus price target of $10.86.
The stock price for SAB Biotherapeutics (NASDAQ: SABS) is $2.58 last updated October 19, 2026 at 4:11 PM EDT.
There are no upcoming dividends for SAB Biotherapeutics.
SAB Biotherapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for SAB Biotherapeutics.
SAB Biotherapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
